Wu Po-Chien, Li Chia-Lun, Chang Yun-Ting, Chen Chih-Chiang, Wu Chen-Yi, Ma Sheng-Hsiang
From the *Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan City, Taiwan.
Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical University, Taipei City, Taiwan.
Dermatitis. 2023 Mar-Apr;34(2):77-84. doi: 10.1089/derm.2022.29019.pwu. Epub 2023 Jan 19.
Since the outbreak of COVID-19, management of atopic dermatitis (AD) has been widely discussed. Key issues include the risk of COVID-19 infection and related outcomes in AD patients, the efficacy and safety of COVID-19 vaccination in AD populations, and management of AD in the COVID-19 pandemic. Recent studies have shown that patients with AD have a slightly increased risk of COVID-19 infection but are not associated with a worse outcome than the non-AD population. COVID-19 vaccination is generally effective and safe in patients with AD. However, temporary discontinuation of certain systemic immunomodulatory agents after vaccination is suggested. During the pandemic, continuation of all immunomodulating agents is suggested, but these agents should be paused when patients with AD are infected with COVID-19 until recovery. Further studies are warranted to investigate the long-term interaction between AD and COVID-19 to aid clinical decisions during the pandemic.
自新冠疫情爆发以来，特应性皮炎（AD）的管理受到了广泛讨论。关键问题包括AD患者感染新冠病毒的风险及相关后果、AD人群接种新冠疫苗的有效性和安全性，以及新冠疫情期间AD的管理。最近的研究表明，AD患者感染新冠病毒的风险略有增加，但与非AD人群相比，其预后并不更差。新冠疫苗接种在AD患者中总体上是有效且安全的。然而，建议接种疫苗后暂时停用某些全身性免疫调节药物。在疫情期间，建议继续使用所有免疫调节药物，但AD患者感染新冠病毒后应暂停使用这些药物，直至康复。有必要进行进一步研究，以调查AD与新冠病毒之间的长期相互作用，以辅助疫情期间的临床决策。
